In a disease where BTK inhibitor discontinuation typically signals rapid progression and a near-absence of reliable salvage options, a 79.2% major response rate in exactly 24 patients is a striking number — particularly because this subset was defined by that very condition: immediately post-BTKi relapse or refractory Waldenström macroglobulinemia.
The CLOVER WaM Phase 2b data presented at ASCO tell a coherent story about iopofosine I-131’s mechanism. The phospholipid drug conjugate platform exploits the lipid metabolism differences in malignant versus normal lymphoplasmacytic cells, delivering iodine-131 with enough selectivity that the only Grade 3 or higher adverse events were cytopenias — notable restraint for a radiotherapeutic. Among the 24-patient mITT cohort meeting the ≥60 mCi total dose threshold whose immediately prior line was a BTKi, overall response rate reached 87.5%, clinical benefit hit 100%, and median duration of response landed at 16 months. That 20% of patients exceeded 30 months of response in a post-BTKi population is the figure that matters most: it suggests iopofosine isn’t rescuing patients temporarily before the same clonal biology reasserts itself.
The regulatory and development logic Cellectar is now executing is aggressive. Breakthrough Designation is already in hand, and the company is pursuing accelerated approval on the strength of these Phase 2 response data while a confirmatory Phase 3 is scheduled to initiate in Q4 2026. That accelerated approval pathway requires the response rate to reasonably predict clinical benefit — the 16-month median DOR gives FDA the durability argument it needs. The Phase 3 design will matter enormously: if Cellectar positions iopofosine as a second-line agent immediately post-BTKi rather than a third-line rescue, the label they earn changes the commercial ceiling entirely, because BTKis are now so thoroughly embedded in frontline WM that the post-BTKi population is large and growing.
The single metric to track from here is the Phase 3 comparator arm selection. If Cellectar can secure a randomized design against a relevant standard — bendamustine-rituximab or venetoclax-based regimens — and preserve this response depth with DOR intact, accelerated approval converts to full approval on a timeline that determines whether iopofosine becomes a standard of care or a niche salvage option.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
